Nithyakalyani Mohan¹*, Anusha Sunder² and Kandappa Himakar Reddy³

¹Transplant and Research, Apollo Hospitals, Chennai, Tamilnadu, India
²Research Associate, Apollo Hospital and Research Foundation, Chennai, Tamilnadu, India
³Molecular Biologist Associate, Siruseri Biotech Park for Women, Chennai, Tamilnadu, India

*Corresponding Author: Nithyakalyani Mohan, Senior Scientist, Transplant and Research, Apollo Hospitals, Chennai, Tamil Nadu, India.

Received: February 19, 2024; Published: February 29, 2024

Abstract

Recent advances in islet cell transplantation have led to insulin independence in a majority of islet transplant recipients. Numerous protocols have been published describing isolation of human pancreatic islets, but often rigorous and systematic assessment of their integrity is lacking.

We have described a simple, effective method for the isolation and purification of human pancreatic islets from the Indian population so that we can facilitate preclinical allogeneic islet transplantation studies in the Indian population. In this study, we propose 2 different patterns for purification via a simple filtration process and also via gradient technology for the optimal generation of islets. We have also assessed the functionality of the insulin producing islet cells purified by both the methods. The technique yields sufficient numbers of pure and viable islets to support preclinical research to develop improved strategies to prevent the immune destruction of the transplanted islet graft.

 Keywords: Diabetes; Beta Cells; Islets; Insulin; Human Pancreas; Purification; Ficoll; Filtration

References

1. Saeedi P., et al. “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9^th edition”. Diabetes Research and Clinical Practice 157 (2019): 107843.
2. Lakey JR., et al. “Technical aspects of islet preparation and transplantation”. Transplant International9 (2003): 613-632.
3. Lacy PE and Kostianovsky M. “Method for the isolation of intact islets of Langerhans from the rat pancreas”. Diabetes 1 (1967): 35-39.
4. McCall MD., et al. “Histopaque provides optimal mouse islet purification kinetics: comparison study with Ficoll, iodixanol and dextran”. Islets4 (2011): 144-149.
5. Mita A., et al. “Antiproinflammatory effects of iodixanol (OptiPrep)-based density gradient purification on human islet preparations”. Cell Transplant12 (2010): 1537-1546.
6. van der Vliet JA., et al. “Pancreatic islet isolation in rats with ductal collagenase distention, stationary digestion, and dextran separation”. Transplantation2 (1988): 493-495.
7. Lake SP., et al. “Bovine serum albumin density gradient isolation of rat pancreatic islets”. Transplantation6 (1987): 805-808.
8. Atwater I., et al. “Isolation of viable porcine islets by selective osmotic shock without enzymatic digestion”. Transplantation Proceedings1 (2010): 381-386.
9. Salvalaggio PR., et al. “Islet filtration: a simple and rapid new purification procedure that avoids ficoll and improves islet mass and function”. Transplantation6 (2002): 877-879.
10. McCall MD., et al. “Histopaque provides optimal mouse islet purification kinetics: comparison study with Ficoll, iodixanol and dextran”. Islets 4 (2011): 144-149.
11. Takaki T and Shimoda M. “Pancreatic islet transplantation: toward definitive treatment for diabetes mellitus”. Global Health Medicine 4 (2020): 200-211.
12. Lakey JR., et al. “Variables in organ donors that affect the recovery of human islets of Langerhans”. Transplantation7 (1996): 1047-1053.
13. Liu X., et al. “Analysis of donor- and isolation-related variables from non-heart-beating donors (NHBDs) using the Kyoto islet isolation method”. Cell Transplantation6 (2008): 649-656.
14. Benhamou PY., et al. “Human islet isolation in 104 consecutive cases. Factors affecting isolation success”. Transplantation 12 (1994): 1804-1810.
15. Matsumoto S., et al. “Analysis of donor factors affecting human islet isolation with current isolation protocol”. Transplantation Proceedings4 (2004): 1034-1036.
16. Balamurugan AN., et al. “Successful human islet isolation and transplantation indicating the importance of class 1 collagenase and collagen degradation activity assay”. Transplantation8 (2010): 954-961.
17. Bellin MD., et al. “Quality of life improves for pediatric patients after total pancreatectomy and islet autotransplant for chronic pancreatitis”. Clinical Gastroenterology and Hepatology9 (2011): 793-799.
18. Sutherland DE., et al. “Total pancreatectomy and islet autotransplantation for chronic pancreatitis”. Journal of the American College of Surgeons4 (2012): 409-426.
19. Balamurugan AN., et al. “A new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products”. Transplantation 7 (2012): 693-702.
20. Chadwick DR., et al. “Human islet purification: a prospective comparison of Euro-Ficoll and bovine serum albumin density gradients”. Acta Diabetology1 (1993): 57-59.
21. Moskalewski S. “Isolation and Culture of the Islets of Langerhans of the Guinea Pig”. General and Comparative Endocrinology 5 (1965): 342-353.
22. Li Baifeng., et al. “An economic, efficient, and rapid device and method for the isolation and purification of mouse islet cells: China Patent ZL201620214060.8” (2016): 2016-11-30.
23. Shapiro AM., et al. “Clinical pancreatic islet transplantation”. Nature Reviews on Endocrinology 13 (2017): 268-277.
24. Farney AC., et al. “Evolution of Islet Transplantation for the Last 30 Years”. Pancreas 1 (2016): 8-20.
25. Moskalewski S. “Isolation and Culture of the Islets of Langerhans of the Guinea Pig”. General and Comparative Endocrinology 5 (1965): 342-353.
26. Moskalewski S. “Beginning of pancreatic islet isolation by collagenase digestion (personal reminiscences)”. Annals of Transplantation3 (1997): 6-7.
27. Berishvili E., et al. “What’s hot and what’s new in beta-cell replacement therapy: highlights from the 16^th Congress of IPITA”. CellR4 4 (2017): e2419.
28. Lyon J., et al. “Research-focused isolation of human islets from donors with and without diabetes at the Alberta diabetes institute isletcore”. Endocrinology 157 (2016): 560-569.
29. Lakey JR., et al. “Variables in organ donors that affect the recovery of human islets of Langerhans”. Transplantation 61 (1996): 1047-1053.
30. Ponte GM., et al. “Toward maximizing the success rates of human islet isolation: Influence of donor and isolation factors”. Cell Transplant 16 (2007): 595-607.
31. Wang Y., et al. “Systematic analysis of donor and isolation factor's impact on human islet yield and size distribution”. Cell Transplant 22 (2013): 2323-2333.
32. Gores PF., et al. “Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience”. Annals of Surgery 215 (1992): 217.
33. Kaddis JS., et al. “Multicenter analysis of novel and established variables associated with successful human islet isolation outcomes”. American Journal of Transplantation 10 (2010): 646-656.
34. Ricordi C., et al. “National institutes of health-sponsored clinical islet transplantation consortium phase 3 trial: Manufacture of a complex cellular product at eight processing facilities”. Diabetes 65 (2016): 3418-3428.
35. Shapiro AM., et al. “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen”. The New England Journal of Medicine 4 (2000): 230-238.
36. Jahr H., et al. “Endotoxin-mediated activation of cytokine production in human PBMCs by collagenase and Ficoll”. Journal of Molecular Medicine1 (1999): 118-120.
37. Jahr H., et al. “Toxic effects of superoxide, hydrogen peroxide, and nitric oxide on human and pig islets”. Transplant Proc. 6 (1995): 3220-3221.
38. Brandhorst H., et al. “Assessment of intracellular insulin content during all steps of human islet isolation procedure”. Cell Transplant5 (1998): 489-495.
39. Carter JD., et al. “A practical guide to rodent islet isolation and assessment”. Biological Procedures Online 11 (2009): 3-31.
40. MacGregor RR., et al. “Small rat islets are superior to large islets in in vitro function and in transplantation outcomes”. American Journal of Physiology-Endocrinology and Metabolism 5 (2006): E771-E779.
41. Lehmann R., et al. “Superiority of small islets in human islet transplantation”. Diabetes3 (2007): 594-603.
42. Farhat B., et al. “Small human islets comprised of more β-cells with higher insulin content than large islets”. Islets 2 (2013): 87-94.
43. Fujita Y., et al. “Large human islets secrete less insulin per islet equivalent than smaller islets in vitro”. Islets 3 (2011): 1-5.
44. Nam KH., et al. “Size-based separation and collection of mouse pancreatic islets for functional analysis”. Biomed Microdevices5 (2010): 865-874.
45. Ramírez-Domínguez M and Castaño L. “Filtration is a time-efficient option to Histopaque, providing good-quality islets in mouse islet isolation”. Cytotechnology2 (2015): 199-206.
46. Cabrera O., et al. “The unique cytoarchitecture of human pancreatic islets has implications for islet cell function”. Proceedings of the National Academy of Sciences of the United States of America7 (2006): 2334-2339.
47. Lakey JR., et al. “Technical aspects of islet preparation and transplantation”. Transplant International9 (2003): 613-632.
48. O'Dowd JF. “The isolation and purification of rodent pancreatic islets of Langerhans”. Methods in Molecular Biology 560 (2009): 37-42.
49. Kim A., et al. “Islet architecture: A comparative study”. Islets 2 (2009): 129-136.

Citation

Citation: Nithyakalyani Mohan., et al. “A Simple, Time Efficient Purification Methodology Providing Good Quality Human Pancreatic Islets in the Indian Population”.Acta Scientific Medical Sciences 8.3 (2024): 161-170.

Copyright

Copyright: © 2024 Nithyakalyani Mohan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.